Yes! We have the plasmids containing Rep2-Cap 2, 5 ,6 , 8 and 9 for AAV production and the packaging plasmids and transfer vector for 2nd and 3rd generation lentivirus vectors. We also possess the FastBac system for rapid generation of bacmids to produce the baculovirus stocks needed to assemble AAVs in insect cells. For adenovirus, we use the pAdEasy adenoviral vector system ready to recombine with your gene of interest in E. coli, using a shuttle vector, to further produce the adenovirus vectors in HEK-293 cells.

Yes! The viral vectors we produce are non-infectious, non-replicative and safe. However, the products produced in HEK-293 cells are considered Biosafety level 2 (BSL-2). Therefore, we often require that clients send us the border forms of their country to help them to fill it up to facilitate a smooth shipping experience.

No. We can proceed with the project having only the sequence of your gene. In this case, we will proceed with the chemical synthesis, then clone the gene in our plasmid vectors and amplify it to the required scale.

AAVs are mainly used for in-vivo gene therapy because they are safe, replication- defective, non-pathogenic viruses causing low-mild immunogenic response and mediate long-term gene expression. On the other hand, lentiviruses (LV) are widely used for ex-vivo CAR-T cell therapy to modify and activate patient immune cells to fight cancer. For this purpose, LVs have several advantages such as transducing dividing and non-dividing cells and mediating long-term expression since the gene is integrated into the target cell chromosome. Adenovirus have multiple applications in vaccination, gene and cancer therapy as they present high packaging capacity, high cell transduction efficiency and can be produced at high titers. The adenovirus DNA does not integrate into the host genome but remains episomal avoiding insertional mutagenesis. During COVID-19 pandemic, major advancements in the manufacturing of adenoviral vectors have been achieved, allowing the production of anti-SARS-CoV-2 vaccines at a global scale.

It varies from project to project. Process development projects are very specific to your needs, so we need to gather all the required information during the initiation phase to provide you as soon as possible with the scope of work, timelines, and cost. For final product request projects, the approximate duration is as follows:

► AAV produced in HEK-293 cells - Approximately 6 weeks including plasmid purification
► LV - Approximately 6 weeks including plasmid purification
► Adenovirus - Approximately 8 weeks
► AAV produced in BV-insect cell system - Approximately 8 weeks